2019 September | Opal option exercise fuels development plan
2019 August | Opal partners in new ARC Research Hub
2019 Mar | Opal Releases Half Year Results Announcement – 31 Dec 2018
2019 Mar | Opal Half-year Financial Report – 31 Dec 2018
2018 Opal Joins Global Antimicrobial Challenge
2018 Opal AGM CEO Presentation
2018 Opal AGM Results of Meeting
2018 Opal AGM Chairman’s Address
2018 Opal Biosciences 2018 Annual Report
2018 Opal Biosciences Notice of Meeting and Proxy Form
2018 August | Opal New Board Addition
2018 July | Opal Information Memorandum Announcement
2018 July | Opal Information Memorandum Document
2018 July | Opal July Presentation
2018 May | BioDiem receives Innovation Connections grant for Opal work
2018 Apr | Half-year Financial Report – 31 Dec 2017
2018 | Completion of Placement and Board change
2018 | Scedosporium patent grant in US and Europe
2017 Oct | Notice of Annual General Meeting – Explanatory Statement and Proxy Form
2017 Jul | Company Update and EOFY 2017 Information
2016 Dec | Half-year Financial Report – 31 December 2016
2016 Nov | New European patents for Opal Biosciences antimicrobial BDM-I
2016 Oct | Results of Meeting-Opal Biosciences
2016 Oct | Opal Biosciences Chairman’s Address
2016 | Opal Biosciences Notice of Meeting and proxy form 2016
2016 Jun | OpalBiosciences Annual Report 2016
2015 Jul | Opal technology presented at the Aust Society for Microbiology Meeting
2015 Jul | Successful grant for BDM-I – Griffith University
2015 Jun | Opal’s anti-infective technology profiled at BIO International Convention, 2015
2015 Jun | Opal Biosciences Update
2015 May | Introducing Opal Biosciences
Send Enquiry
[/text_output] [/vc_column]Contact
Opal Biosciences Ltd
ACN 605 631 963
Telephone: + 61 3 9692 7240
Facsimile: + 61 3 9077 9233
Registered Office
Opal Biosciences Ltd
Level 4, 100 Albert Road
South Melbourne
Victoria 3205